Skip to main content

Sloan-Kettering Joins Sigma-Aldrich's RNAi Partnership Program

NEW YORK (GenomeWeb News) – Memorial Sloan-Kettering Cancer Center has joined Sigma-Aldrich’s RNAi Partnership Program, the St. Louis, Mo.-based firm said today.
 
Sigma-Aldrich said that members of the program gain access to products in its functional genomics portfolio including shRNA libraries developed by the RNAi Consortium that target more than 15,000 human genes and 15,000 mouse genes. Sigma-Aldrich is a member of the RNAi Consortium.
 
The RNAi Consortium was established by the Broad Institute in 2004. The public/private alliance of RNAi researchers is developing genome-scale sets of virally expressed shRNAs targeting mouse and human genes.
 
New York City-based Sloan-Kettering joins a list of academic and other research institutes including the Cleveland Clinic, the Harvard Stem Cell Institute, Washington University of St. Louis, Princeton University, the Wistar Institute, and Rutgers University, as members of the program.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.